ANDA 76801, held by PharmoBedient. Pioglitazone Hydrochloride.
As of Nov 19, 2026, ANDA 76801 (Pioglitazone Hydrochloride), held by PharmoBedient, was first approved by FDA on Aug 17, 2012, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 17, 2012 | Original application | Approved |
| Pioglitazone HydrochlorideEQ 15MG BASE · tablet;oral | Pioglitazone Hydrochloride | Discontinued |
| Pioglitazone HydrochlorideEQ 30MG BASE · tablet;oral | Pioglitazone Hydrochloride | Discontinued |
| Pioglitazone HydrochlorideEQ 45MG BASE · tablet;oral | Pioglitazone Hydrochloride | Discontinued |
| Nov 29, 2018 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 29, 2018 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jul 21, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 17, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters